KB801

AXP000197.1 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Targets
NGF
Originator
Krystal Biotech
Sponsor
Krystal Biotech

Names

NameTypeSource
KB801preferred name, codecurator, press
EMERALD-1 ambiguoussynonympress

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-defective HSV-1 backbone; NGF cassette
Transgenes
NGF
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06999733A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisRecruitingPhase 1/22025-07-072026-1260Neurotrophic Keratitis

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 39798579Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.Lancet (London, England)2025name in title: EMERALD-1

Other papers

Preclinical studies, reviews and other papers that name it.

No confirmed other papers yet.

Unconfirmed matches (3)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41503570Impact of LEAP-012 and EMERALD-1 in the management of HCC.JHEP reports : innovation in hepatology2026name in title: EMERALD-1
PMID 41046144Unexplained early deaths in EMERALD-1: is liver failure the reason?Lancet (London, England)2025name in title: EMERALD-1
PMID 41046145Unexplained early deaths in EMERALD-1: is liver failure the reason? - Authors' reply.Lancet (London, England)2025name in title: EMERALD-1

Notes

Redosable eye-drop HSV-1 gene therapy driving corneal/ocular surface expression of nerve growth factor (NGF) in neurotrophic keratitis; phase 1/2 EMERALD-1, NCT06999733, dosed twice weekly for 8 weeks. The press release does not name the vector explicitly; HSV-1 is Krystal's platform.

How to cite

KB801 (AXP000197.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000197.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.